The abstract is read at the publisher; the summary is JClub's.
MSI-high is rare in sarcomas (<1%), but in a clinically sequenced cohort it concentrates in pleomorphic and radiation-associated subtypes, including PRMS (36%).
- Why it matters: Sarcoma MSI biology and treatment relevance are unclear, limiting how often patients can be identified for mismatch repair–linked evaluation and immune checkpoint inhibitor consideration.
- What they did: MSI status was measured in 6,449 bone and soft-tissue tumors, including 5,992 sarcomas, using targeted next-generation sequencing with validated pipelines. In 11 PRMS cases, 4 were MSI-high (36%), and 6 of 24 radiation-associated sarcomas were MSI-high (25%).
- The result: In 11 ICI-treated patients, 3 had durable clinical benefit lasting more than 6 months, with higher PD-L1 in responders, supporting targeted screening despite heterogeneous responses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.